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Mutations in the tetratricopeptide repeat domain 7A (TTC7A) gene cause very early
onset inflammatory bowel diseases (VOIBD) or multiple intestinal atresia associated
with immune deficiency of various severities, ranging from combined immune deficiency
to mild lymphopenia. In this manuscript, we report the clinical, biological and
molecular features of a patient born from consanguineous parents, presenting with
recurrent lymphoproliferative syndrome and pan-hypergammaglobulinemia associated
with chronic intestinal pseudo obstruction (CIPO). Genetic screening revealed the novel
c.974G>A (p.R325Q) mutation in homozygosity in the TTC7A gene. The patient’s
phenotype differs significantly from that previously associated with TTC7A deficiency in
humans. It becomes closer to the one reported in the ttc7a-deficient mice that invariably
develop a proliferative lymphoid and myeloid disorder. Functional studies showed that
the extreme variability in the clinical phenotype couldn’t be explained by the cellular
phenotype. Indeed, the patient’s TTC7A mutation, as well as the murine-ttc7 mutant,
have the same functional impact on protein expression, DNA instability and chromatin
compaction, as the other mutations that lead to classical TTC7A-associated phenotypes.
Co-inheritance of genetic variantsmay also contribute to the unique nature of the patient’s
El-Daher et al. An Unexpected Phenotype Associated With TTC7A Deficiency
phenotype. The present case report shows that the clinical spectrum of TTC7A deficiency
is much broader than previously suspected. Our findings should alert the physicians to
consider screening of TTC7A mutations in patients with lymphoproliferative syndrome
and hypergammaglobulinemia and/or chronic intestinal pseudo-obstruction.
Keywords: tetratricopeptide repeat domain 7A, lymphoproliferative syndrome, intestinal pseudo-obstruction, fsn
mouse, mutant’s cell phenotype
INTRODUCTION
In humans, biallelic loss-of-function mutations in
tetratricopeptide repeat domain 7A (TTC7A) have been
shown to cause intestinal and immune disorders of variable
severity. The disease phenotype ranges from very-early-onset
inflammatory bowel disease (VOIBD) to multiple intestinal
atresia, accompanied by mild lymphopenia (ELA) or even
combined immunodeficiency (MIA-CID, respectively) (1–4).
The TTC7A protein is a member of the tetratricopeptide
repeat family and is thought to interact with the components
of many different macromolecular complexes. For example,
TTC7A reportedly interacts with the phosphatidylinositol
4-kinase alpha (PI4K), which catalyzes the production of
phosphatidylinositol 4-phosphate at the plasma membrane,
and the protein EFR3 homolog B (EFR3), which may serve
as a membrane anchor for PI4K (3, 5). Furthermore, TTC7A
downregulates the RhoA-ROCK signaling pathway and the
latter’s downstream targets involved in actin dynamics (2, 4).
Lastly, it was recently reported that a high proportion of the cell’s
TTC7A is located in the nucleus, where the protein modulates
transcription and chromatin structure (6). Hence, TTC7A
have many functions, but the pathophysiological mechanisms
underlying the disorders presented by TTC7A-deficient patients
have yet to be fully characterized.
CASE REPORT
Here, we report on a male patient born at 37 weeks of
gestation in a twin pregnancy (birth weight: 2730 g; birth
length: 47 cm) to consanguineous parents of Algerian descent
(Figure 1A). Soon after birth, the infant displayed abdominal
bloating, frequent liquid stools, and failure to thrive. Neither
vomiting nor rectal bleeding were observed. The results of clinical
examination were otherwise unremarkable. The replacement of
breast milk by an extensive protein hydrolysate did not lead
to an improvement. At the age of 11 months, the infant was
hospitalized following an aggravation of the digestive symptoms
that necessitated parenteral nutrition. The results of a sweat test,
abdominal ultrasound examination, serologic assay (for HSV,
CMV, EBV, and mycoplasma), a urine catecholamine test and
auto-immune investigations were all negative. Gastroduodenal
and rectal endoscopy did not reveal any abnormal macroscopic
features. A histology assessment highlighted the presence of
non-specific proctitis and gastro-duodenitis, characterized by a
moderate inflammatory infiltrate containing a high proportion
of mononuclear cells and a few eosinophils (Figure 1B). The
duodenal crypt epithelium showed excessive apoptosis. Sections
of antrum were negative for Helicobacter pylori. A diagnosis
of chronic intestinal pseudo-obstruction (CIPO) was suggested
by the impaired upper digestive tract function, segmental
dilatation of the jejunum and ileum, an atypical rectoanal
inhibitory reflex. The diagnosis was confirmed on a rectal
surgical biopsy that showed numerous submucosal nerves and
myenteric plexus of variable size with many ganglion cells
(Supplementary Figure 1). Hair microscopical analysis revealed
no anomalies including absence of trichorrhexis nodosa.
At the age of 14 months, the patient presented with prolonged
fever complicated by acute respiratory distress syndrome
(ARDS), multiple lymphadenopathies (in the axillary, inguinal,
mediastinal, and retroperitoneal areas) and hepatosplenomegaly
(Figure 1C). A histologic assessment of an axillary lymph node
showed a slight hyperplasia of the T cell zone, mostly consisting
in small CD4+ T lymphocytes, together with histiocytes and
dendritic cells, although the overall architecture was unaffected
(data not shown). Immunologic profiling of the patient’s
peripheral blood mononuclear cells revealed moderate CD8+
and NK lymphopenia, a normal CD4+ lymphocyte count,
normal lymphocyte proliferation in responses to mitogens and
tetanus toxoid antigens, and hypergammaglobulinemia (IgG,
IgA, IgM, and IgE) (Table 1 and data not shown). The patient
improved after the initiation of corticosteroid therapy and
then azathioprine that was given for 12 months. The patient
experienced a CMV infection and severe varicella 6 months
later, both with a favorable outcome. Despite the persistence
of intestinal bloating, the recovery of normal oral feeding
with relatively normal stools made it possible to discontinue
parenteral nutrition at the age of 2.
At the age of 6 and a half, 3 months after the withdrawal
of corticosteroid therapy, the patient’s lymphoproliferative
syndrome relapsed. A histologic assessment of several
lymphadenopathies showed an important expansion of the
T cell area with a polymorphic infiltrate made of medium
to large-sized lymphoid cells, plasma cells, eosinophils and
macrophages, associated with centrofollicular B lymphoid
depletion. T lymphocytes weremainly CD3+CD8+ differentiated
lymphocytes expressing granzyme B and PD1 (Figure 1D).
There was no evidence of Epstein-Barr Virus (EBV) infection
by Epstein-Barr virus–encoded small RNA (EBER) in situ
hybridization. A bone marrow biopsy highlighted a moderate
plasma cell hyperplasia and an excess of interstitial CD8+
T lymphocytes. Immunologic profiling evidenced marked
hypergammaglobulinemia of all isotypes tested (IgG, IgA,
IgM) that was associated with moderate CD4+ and CD8+
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FIGURE 1 | Family pedigree, TTC7A mutation, and histopathological findings in reported patient. (A) From top to bottom: family pedigree; Sanger sequencing
chromatogram depicting the c.974G>A mutation in TTC7A gene; alignment of the amino acid (aa) surrounding the conserved R325 residue in TTC7A homologs from
8 species; illustration of TTC7A protein in which purple boxes indicate tetratricopeptide repeats (TPRs) domains, the R325Q homozygous mutation identified in
reported patient (Il4 m/m) is highlighted in red, in contrast to mutations previously reported in other TTC7A patients and relevant to this study, which are indicated in
black. (B) Histologic analysis of duodenal biopsies from P_R325Q patient (11 months old). Hematoxylin and Eosin (H&E) staining was performed, magnifications of the
left and right panels are 100 and 400X, respectively. In the higher magnification panel, red circles denote excess apoptotic epithelial cells in the crypts. (C) Scanners
showing hepatosplenomegaly (left, white arrow) and lymphadenopathies (right, blue arrow) performed in P_R325Q patient at the age of 14 months. (D) Histologic
analysis of axillary lymph nodes from P_R325Q patient at 6.5 years. H&E staining (HES) (top left, 400X magnification) of a T cell area showed a polymorphic expansion
of lymphoid cells admixed with plasma cells, macrophages and eosinophils. CD3 (400X magnification) positive T cells were often medium and large. These T cells
were predominantly CD8, with expression of PD1 (200X magnification) and granzyme B (400X magnification). CD4 staining (200X magnification) identified numerous
macrophages and a minority of lymphocytes.
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TABLE 1 | Immunological phenotypes of TTC7A patient carrying R325Q
homozygous mutation.
Lymphocytes Age 17 months Age 6.5 years
CELL COUNTS, CELLS/µl (NORMAL RANGE)
CD3+ T cells 2,940 (2,100–6,200) 2,950 (1,200–2,600)
CD4+ 2,156 (1,300–3,400) 1,578 (650–1,500)
CD8+ 588 (620–2,000) 1,327 (370–1,100)
CD45RA+CD4+% 55 (73–86) 49 (58–70)
CCR7+CD45RA+/CD8+% N/A 7 (52–68)
CCR7+CD45RA−/CD8+% N/A 2 (3–4)
CCR7−CD45RA−/CD8+% N/A 68 (11–20)
CCR7−CD45RA+/CD8+% N/A 23 (16–28)
CD19+ B cells 1,764 (720–2,600) 251 (273–860)
CD27+/CD19+% N/A 11 (8.1–33.3)
CD27− IgD+/CD19+% N/A 88 (59.7–88.4)
CD27+ IgD+/CD19+% N/A 1 (2.9–17.4)
CD16+CD56+ NK cells 98 (180–920) 143 (100–480)
Age 17 months Age 6.5 years
CELL COUNTS, CELLS/ µl (NORMAL RANGE)
Polymorphonuclear
- Neutrophils 10,500 (1,500–8,500) 12,900 (1,800–8,000)
- Eosinophil 3,000 (0–300) 800 (0–300)
Monocytes 1,000 (200–1,000) 1,800 (200–1,000)
Platelets 503,000(175,000–500,000) 956,000(175,000–420,000)
Hemoglobin g/dl 11.7 (10.5–12) 9.4 (11.5–13.5)
Immunoglobin Age 17 months Age 6.5 years
SERUM IMMUNOGLOBIN LEVELS (NORMAL RANGE)
IgG g/L 13.24 (4.57–8.49) 26.83 (5.82–11.54)
IgA g/L 0.87 (0.27–0.86) 9.89 (0.46–1.57)
IgM g/L 7.06 (0.47–1.31) 9.06 (0.54–1.55)
IgE UI/ml 12 000 (<114) N/A
N/A, not available.
T lymphocytosis, a low proportion of naïve CD4+ and
CD8+ T lymphocytes, a high proportion of CD8+ memory
T lymphocytes, and moderate B cell lymphopenia (Table 1).
Reintroduction of azathioprine led to full resolution of the
lymphoproliferative syndrome. Two years later, the patient is still
on azathioprine maintenance therapy, and there are no clinical
signs of lymphoproliferation.
GENETIC AND FUNCTIONAL
CHARACTERIZATION OF
TTC7A-DEFICIENCY
Analysis with 301-gene primary immunodeficiency (PID) panel
and then Sanger sequencing revealed a novel homozygous
mutation in TTC7A exon 7 of (NM_020458.3: c.974G>A)
on chromosome 2, leading to p.R325Q (Figure 1A). The
patient’s father and one of the three healthy siblings were
heterozygous for the mutation and the two remaining siblings
were wild type (Figure 1A and Supplementary Figure 2).
Samples from the mother were not available. A segregation
analysis of polymorphic markers spanning the TTC7A locus
identified a homozygous region in the patient and was in
accordance with the mutation segregation in the family
(Supplementary Figure 2). The mutation affects a highly
conserved amino acid at position 325 in the TTC7A protein
(Figure 1A). The overall minor allele frequency (MAFs) is
0.00024 in gnomAD and the mutation is predicted to be
pathogenic by in silico soft-wares (PolyPhen-2 (score: 0.07),
SIFT (0.01) and CADD (24.3)). Based on the literature data
and our findings, we considered that a novel homozygous
mutation in TTC7A was the most plausible cause of
patient’s disease.
The phenotype of the patient described here differs
significantly from that previously associated with TTC7A
deficiency in humans; indeed, some of the features
contrasted sharply. In particular, the patient presented
with recurrent lymphoproliferative syndrome and pan-
hypergammaglobulinemia but there was no evidence of
disruption of the digestive tract’s mucosal architecture,
while CIPO was diagnosed. Hence, we decided to assess
the functional consequences of the identified TTC7A mutant
(p.R325Q). As seen with most mutants studied to date, TTC7A
protein expression level of the R325Q mutant was lower in B
lymphoblastoid cell line (Figure 2A) and in T lymphoblasts
(Supplementary Figure 3A); the nucleoplasmic and chromatin-
bound fraction were particularly low. Thus, the TTC7A-R325Q
mutant protein appeared to be unstable leading to partial
protein degradation, as seen for other reported mutants. The
TTC7A protein stabilizes subunits like EFR3 in the complex
that modulates the phospholipid composition at the plasma
membrane (5). Accordingly, we found that patient’s B cells
expressed very low levels of EFR3 (Figure 2B). We recently
showed that TTC7A in the nucleus regulates DNA accessibility,
DNA stability, and chromatin condensation (6). By using
micrococcal nuclease digestion assay and accumulation of 53BP1
foci, we observed a time-dependent increased in sensitivity to
digestion and the spontaneous formation of many discrete 53BP1
foci in R325Q mutant cells, just as is seen in TTC7A-deficient
cells from patients carrying other mutations (Figures 2C,D,
Supplementary Figures 3B,C) (6). The TTC7A-R325Q mutant
also had a detectable impact on chromatin condensation; the
chromatin in B cell metaphases had a swollen, fuzzy appearance,
as observed for previously reported TTC7A mutants with
ELA and MIA-CID phenotypes (Figure 2E) (6). Thus, patient’s
unexpected clinical and immunological phenotype corresponds
to a recurrent lymphoproliferative syndrome associated with
a loss-of-function mutation in TTC7A. On the subcellular
level, the functional characteristics of the R325Q mutant are
the same as those seen for TTC7A mutants associated with
the ELA and MIA-CID phenotypes. We looked for additional
genetic alterations that might have modified patient’s clinical
phenotype. Using whole-exome sequencing, we identified an
additional homozygous mutation in Ski2 like RNA helicase
(SKIV2L) gene on chromosome 6 (c.1447C>T leading to
Frontiers in Immunology | www.frontiersin.org 4 November 2019 | Volume 10 | Article 2592
El-Daher et al. An Unexpected Phenotype Associated With TTC7A Deficiency
FIGURE 2 | Phenotypic consequences of R325Q mutation. (A) The expression level of TTC7A protein (96 kDa) is decreased in the different cellular compartments
extracted from B lymphoblastoid cell lines (B-LCLs) from R325Q_TTC7A (P_R325Q) patient and from TTC7A-deficient patient (P2_E71K) as compared to healthy
donors (Ctr). β actin was used as an internal loading control in the western blot. (B) The expression level of the protein EFR3 homolog A (EFR3A) is decreased in
B-LCLs from R325Q_TTC7A patient and from TTC7A-deficient patients (P*/L478P and P*/A524V), as compared to control. The level of EFR3A protein was
determined by western bot and the graph represents average level from three independent experiments, error bars indicate standard error of the mean (± SEM).
Previously reported TTC7A patients are indicated as Ps_TTC7A when grouped. Unpaired t-test; **p = 0.002, ****p < 0.0001. (C) DNA accessibility is increased in
B-LCLs from P_R325Q and from Ps-deficient patients (P1_E71K, P2_E71K, P*/L478P) as compared to control. The concentration of digested DNA was measured at
different time points and the ratio between small and large size DNA fragments are shown in the graph. The graph indicates the average of DNA ratio measured from
four independent experiments (± SEM), Mann-Whitney test, **p < 0.01. (D) DNA damage is increased in patients’ B-LCLs as compared to control, with an
accumulation of 53BP1 foci. Left: immunostainings of 53BP1 imaged by confocal microscopy, Right: quantification of 53BP1 foci number. Graph represents the
average count obtained from two independent experiments (Mean ± SEM). Total number of cells in control = 508; P2_E71K n = 315; P_R325Q n = 452; Sidak’s
multiple comparisons test, ****p < 0.0001. (E) Impaired chromatin condensation of patients’ B-LCLs as compared to control. Left: chromosomes are stained with
DAPI and imaged by confocal microscopy. Right: quantification of chromosomes with abnormal structure was performed on four independent experiments and the
average count is shown in the graph (± SEM). Unpaired t-test, p = 0.0076 for Ps_TTC7A (P1_E71K, P2_E71K and P*/L478P) vs. control, and p = 0.006 for
P_R325Q vs. control. Scale bar: 10 microns.
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p.Arg483Cys). This mutation was absent or heterozygous in
the healthy family members. SKIV2L deficiency results in
tricohepatoenteric syndrome (THES) (7). The homozygous
c.1447C>T SKIV2L mutation was previously reported in a
patient of African descent, displaying some of the features
of THES (i.e., intrauterine growth retardation, VOIBD, liver
disorders and immune defects) but lacking others (i.e., facial
dysmorphism, skin and hair abnormalities, and cardiac defects)
(7). With the exception of VOIBD, our patient did not display
features of THES. Thus, the additional SKIV2L alteration is
unlikely to account for our patient’s clinical phenotype. However,
we cannot rule out the possibility whereby, co-inheritance of this
second genetic change contributes to the unique nature of the
patient’s phenotype relative to other reported cases of TTC7A-
deficiency. Co-inheritance of genetic modifiers is increasingly
been detected, thanks to next-generation sequencing, and can
broaden phenotype heterogeneity (8). This has been recently
illustrated in a patient carrying two homozygousmutations in the
myeloid differentiation primary response protein 88 (MYD88)
and caspase-associated recruitment domain-containing protein
9 (CARD9) genes (9), or in the interferon alpha receptor 1 and 2
(IFNAR1 and IFNGR2) genes (10), who presented with atypical
phenotype considering the phenotype associated with each of
the altered genes.
Interestingly, patient’s immune phenotype is reminiscent
of that observed in the Ttc7a-deficient fsn mouse. Fsn mice
invariably develop a proliferative lymphoid and myeloid
disorder, with hyperplasia of the spleen and lymph nodes
(11). We thus assessed the functional consequences of
Ttc7a deficiency in fsn splenocytes. We similarly found that
Ttc7a mutation impaired Ttc7a protein expression, increased
DNA accessibility and instability and modified chromosome
compaction (Supplementary Figure 4). Reduction of EFR3
expression was previously reported in this murine model, further
highlighting the cross-species conservation of the TTC7A’s
interactions and function (5). The mechanism(s) underlying
phenotypic variability in these different contexts of TTC7A
deficiency remains difficult to understand. Given TTC7A’s
broad subcellular distribution (i.e., at the plasma membrane, in
the cytoplasm and nucleus) and many molecular interactions
(2, 3, 5, 6) that converge to regulate cell homeostasis, we suggest
each mutant can differentially alter specific protein-protein
interactions, and thus lead to marked differences between the
patients’ phenotypes.
CONCLUDING REMARKS
To date, TTC7A deficiency has been associated with intestinal
disorders of variable severity (early and severe bloody diarrhea,
apoptotic enterocolitis and atresia or inflammatory bowel
disease), and immune phenotypes that range from severe
lymphopenia and pan-hypogammaglobulinemia to the absence
of immunodeficiency. The present case report shows that
the clinical spectrum of TTC7A deficiency is even broader
than previously suspected. Our findings should alert the
physicians to consider screening of TTC7A mutations in
patients with chronic intestinal pseudo-obstruction and/or
lymphoproliferative syndrome and hypergammaglobulinemia.
As far as we can tell, variability in the clinical phenotype is not
explained by the cellular phenotype.
MATERIALS AND METHODS
Informed Consent
Genetic studies and data collection procedures were approved
by the local investigational review board and the French
Advisory Committee on Medical Research (IRB registration #
00001072, n◦ID-RCB/EUDRACT:2015-A01170-49). The family
gave written informed consent for the publication of this case
report. The results provided were kept anonymous. Patients
with the E71K, P∗/L478P, and P∗/A524V mutations have been
previously reported (4, 6), all of whom had given their consent
to participation in the study.
Patient Cell Culture
Blood samples were collected from the patients and control
subjects. Peripheral Blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation using Ficoll-Paque.
B-lymphoblastoid cell lines (B-LCLs) transformed with EBV as
described previously (2). Primary T lymphocytes were stimulated
for 2 days with phytohemagglutinin (PHA) (5µg/ml; Sigma-
Aldrich, St Louis, Mo) and human Interleukin-2 (IL-2) (50–
200 U/mL; PeproTech, Rocky Hill, NJ) in Panserin medium
(PAN-Biotech GmbH, Aidenbach, Germany) supplemented
with 10% human AB serum (S4190-100 eurobio life science).
Cells were expanded up to 7–12 days after activation in full
media containing 100U IL2. B-LCLs were cultured in RPMI
medium 1640+Glutamax (Gibco, ref 61870-010) supplemented
with 10% Fetal Bovine Serum (Gibco), sodium pyruvate
(1mM, LifeTechnologies) and penicillin and streptomycin (100
U/ml, LifeTechnologies).
Immunohistochemistry
For morphological studies, duodenum and lymph node paraffin-
embedded sections were stained with H&E. Immunostaining
of lymph node section was performed as previously reported
(2) with primary antibodies rabbit anti-CD3 (polyclonal, Dako),
mouse anti-CD4 (clone 4B12, Thermo Scientific), mouse anti-
CD8 (clone C8/144B, Dako), mouse anti-PD1 (NAT105, Abcam)
and mouse anti-granzyme B (clone NCL, Leica).
Ttc7a-deficient Mice and Cell Culture
Bone marrow-derived dendritic cells (BMDC) from homozygous
Ttc7a fsn/fsn mice and their respective control littermates were
obtained as previously reported. T splenocytes were stimulated
with coated 2 µg/ul anti-CD3 (Clone 500A2, Ref 553238, BD)
and soluble 1 µg/ul anti-CD28 (100 IU/mL; PeproTech, Rocky
Hill, NJ) for 2 days. Cells were cultured in DMEM GlutaMax
(Invitrogen, Ref 31966-021), Fetal Bovine Serum (Gibco),
sodium pyruvate and MEM NEAA (1mM, LifeTechnologies),
penicillin/streptomycin (100 U/ml, LifeTechnologies), B-
mercaptoethanol (1/1000, Gibco, Ref 31350-010), and human
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Interleukin-2 (100 U/ml). Cells were expanded up to 8–12 days
after activation.
Antibodies
Antibodies for immunoblots were obtained from the following
commercial sources: αtubulin (abcam ab80779), 53BP1 (novus
NB100-304), beta actin (genetex, GTX629630) and EFR3A
(Sigma Ab2). TTC7A primary antibody has been previously
described (4). Secondary antibodies used are Horseradish
peroxidase coupled goat anti-Rabbit or mouse IgG (H + L) or
are coupled to Alexa Fluor 488 and purchased from molecular
probes (ThermoFisher).
Protein Fractionation,
Immunoprecipitation, and Immunoblotting
Subcellular fractionation enabled stepwise separation of
cytoplasmic, membrane, nuclear soluble and chromatin-
bound proteins were performed as previously reported
(6) by using the ThermoFisher Kit (78840), following
manufacturer’s instructions.
Immunoprecipitations and immunobloting of Ttc7a in
BMDCs was done as previously described (6) and according to
standard procedure.
Immunocytochemistry
Cells were deposited on poly-L-lysine coated coverslip and
fixed with 4% paraformaldehyde in PBS for 20min. Fixed cells
were treated with 0.1M glycine for 30min, permeabilized with
0.5% Triton X-100 in PBS for 15min. 53BP1 antibody (1/200)
was incubated at room temperature for 1 h. Coverslips were
washed and secondary antibody was incubated for 1 h. Cells were
counterstained with DAPI andmounted with proLong Gold anti-
bleaching solution (ThermoFisher P36935) and imaged by using
LSM700 confocal microscope.
Chromosome Spreading
Cells were blocked in metaphase using nocodazole at final
concentration of 100 nM for 18 h. Cells were recovered and
pelleted in cold PBS. Cells were resuspended in hypotonic buffer
(75mM KCl) during 15min at 37◦C, then transferred on ice
and an equal volume of cold hypotonic solution containing
0.1% Tween20 was added in order to help spreading. Cells
were immediately centrifuged in a cytofunnel chamber onto
glass microscope slides during 5min at 800 rpm. Slides were
transferred to a coplin jar containing KCM solution (120mM
KCl, 20mM Nacl, 10mM Tris Hcl ph 7.5, 0.1% TritonX100)
freshly made and incubated 7min, then fixed 10min in 2%
paraformaldehyde. Slides were washed with KCM solution,
staining with DAPI, and mounted with proLong gold anti-fade
reagent and imaged by using LSM700 confocal microscope.
Micrococcal Nuclease Digestion Assay
Control and patient lymphocytes were harvested at 1 × 106
cells per time point. Nuclei were isolated by hypotonic lysis
and micrococcal assay performed using the episcope nucleosome
preparation kit (Takara, cat 5333) and following the instructions
of the manufacturer. DNA was extracted using nucleospin
PCR clean-up kit (Macherey-Nagel, ref 740609). DNA size and
concentration were assessed by using the Fragment Analyzer
Automated CE System (Advanced Analytical). We used the
High Sensitivity NGS Fragment Analysis Kit DNF-474 and the
PROSize 2.0 Software for accurate measurement.
Statistical Analysis
Statistical analyses were conducted using Prism 6 software. Tests
and p-values are indicated in figure legends.
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